

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 33960

**Title:** Real-World Efficacy of Daclatasvir and Asunaprevir with Respect to Resistance-Associated Substitutions

**Reviewer's code:** 00068273

**Reviewer's country:** Italy

**Science editor:** Yuan Qi

**Date sent for review:** 2017-03-17

**Date reviewed:** 2017-03-17

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Very interesting paper on DCV and ASV efficacy in HCV patients; some bias are present.

1) SVR at 12 could be shorter, even if significant; is it possible to look at SVR at 24? 2) Serum markers of liver fibrosis should ameliorate after treatment, contemporary to biochemical and virological markers; Authors should give data on this topic.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 33960

**Title:** Real-World Efficacy of Daclatasvir and Asunaprevir with Respect to Resistance-Associated Substitutions

**Reviewer's code:** 03656586

**Reviewer's country:** China

**Science editor:** Yuan Qi

**Date sent for review:** 2017-03-17

**Date reviewed:** 2017-04-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Although there are some similar reports about daclatasvir (DCV) and asunaprevir (ASV), we are still intested in more detailed data from different center to assess the effect of DCV+ ASV on antivirus. My questions are as follows: 1 there have been quite a few reports about the SVR12 rates of DCV+ASV. We hope that the author can provide SVR24, even SVR48, as much as possible. 12 weeks should not be the end of the clinical treatments. 2. Daclatasvir (DCV) is a NS5A replication complex inhibitor, ASV is a NS3 protease inhibitor. RASs including NS5A:L31, and, NS3:D168, and Y93 were detected before and after treatment in author's study. But why only analyze the correlation between SVR12 and NS5A RASs. it's better to add the correlation analysis between SVR12 and NS3 RASs. 3. There are too many typographical errors to read in the word manuscript.